Cargando…
Study design of GENERAL (general practitioners and embolism prevention in NVAF patients treated with rivaroxaban: Real-life evidence): A multicenter prospective cohort study in primary care physicians to investigate the effectiveness and safety of rivaroxaban in Japanese patients with NVAF
BACKGROUND: Rivaroxaban, a direct oral anticoagulant (DOAC), has become available for stroke prevention in patients with non-valular atrial fibrillation (NVAF). However, little is known about its effectiveness and safety when prescribed by general practitioners in real-life settings. METHODS: GENERA...
Autores principales: | Kusano, Kengo, Akao, Masaharu, Tsuji, Hikari, Matsui, Kunihiko, Hiramitsu, Shinya, Hatori, Yutaka, Odakura, Hironori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529321/ https://www.ncbi.nlm.nih.gov/pubmed/28765760 http://dx.doi.org/10.1016/j.joa.2016.12.001 |
Ejemplares similares
-
Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016) -
Assessment of DOAC in GEriatrics (
Adage
Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients
por: Foulon-Pinto, Geoffrey, et al.
Publicado: (2023) -
Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)
por: Berger, Jeffrey S., et al.
Publicado: (2021) -
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
por: Berger, Jeffrey S., et al.
Publicado: (2023) -
Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study
por: Deitelzweig, Steve, et al.
Publicado: (2020)